Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase P1 gene (GSTP1) in prostate cancer

BMC Urology

Volumn 6, Issue , 2006, Pages

  Kollermann, Jens ^a,b   Kempkensteffen, Carsten ^a   Helpap, Burkhard ^c   Schrader, Mark ^a   Krause, Hans ^a   Muller, Markus ^d   Miller, Kurt ^a   Schostak, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Hegau Bodensee Hochrhein Klinikum   (Germany)

^d KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; PARAFFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DETOXIFICATION; ENZYME ASSAY; GLEASON SCORE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; METHYLATION; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TUMOR BIOPSY;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; DNA METHYLATION; DRUG MONITORING; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33747285144     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-6-15     Document Type: Article

References (15)

1. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001, 58(3):417-424.
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28(3):555-565.
3. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K: Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004, 172(5 Pt 1):1865-1870.
4. Bastian PJ, Nakayama M, De Marzo AM, Nelson WG: [GSTP1 CpG island hypermethylation as a molecular marker of prostate cancer]. Urologe A 2004, 43(5):573-579.
5. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, Miller K: Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000, 60(21):5941-5945.
6. Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M, Miller K: DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001, 58(3):335-338.
7. Goessl C, Muller M, Miller K: Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancer. Prostate Cancer Prostatic Dis 2000, 3(S1):S17.
8. Kollermann J, Muller M, Goessl C, Krause H, Helpap B, Pantel K, Miller K: Methylation-specific PCR for DNA-based detection of occult tumor cells in lymph nodes of prostate cancer patients. Eur Urol 2003, 44(5):533-538.
9. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG: Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 1994, 91(24):11733-11737.
10. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, Kawahara M, Nakagawa M, Kane CJ, Carroll PR, Dahiya R: Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 2005, 11(18):6582-6588.
11. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992, 89(5):1827-1831.
12. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93(18):9821-9826.
13. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D: Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001, 93(22):1747-1752.
14. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG: Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005, 11(11):4037-4043.
15. Helpap B, Bocking A, Dhom G, Faul P, Kastendieck H, Leistenschneider W, Muller HA: [Classification, histologic and cytologic grading and regression grading of prostate cancer]. Urologe A 1985, 24(3):156-159.